Conrad Chan

989 citations

32 papers · 772 indexed · h-index 16

Impact in

Radiology, Nuclear Medicine and Imaging top 5%
- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Medical Imaging Techniques and Applications
Structural Biology top 10%

Papers in ⓘ

Radiology, Nuclear Medicine and Imaging 30
- Radiopharmaceutical Chemistry and Applications 26
- Monoclonal and Polyclonal Antibodies Research 17
- Medical Imaging Techniques and Applications 6
Oncology 21
- HER2/EGFR in Cancer Research 17
- Cancer Immunotherapy and Biomarkers 3

Co-authors: Raymond M. Reilly (30 shared papers)Zhongli Cai (14 shared papers)Katherine A. Vallis (2 shared papers)Deborah A. Scollard (7 shared papers)Jean‐Philippe Pignol (2 shared papers)Karen Lam (5 shared papers)Paul Chen (3 shared papers)Niladri Chattopadhyay (1 shared paper)
Journals: Nuclear Medicine and Biology (8 papers)Molecular Pharmaceutics (5 papers)EJNMMI Radiopharmacy and Chemistry (3 papers)Applied Radiation and Isotopes (2 papers)Journal of Nuclear Medicine (2 papers)
Partner nations: Canada United Kingdom Hong Kong

In The Last Decade

Conrad Chan

31 papers receiving 765 citations

Peers

Countries citing papers authored by Conrad Chan

Since Specialization

Citations

This map shows the geographic impact of Conrad Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Conrad Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Conrad Chan more than expected).

Fields of papers citing papers by Conrad Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Conrad Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Conrad Chan. The network helps show where Conrad Chan may publish in the future.

Co-authors

The 25 scholars most cited alongside Conrad Chan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Conrad Chan Line = papers co-authored together Conrad Chan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer Journal of Nuclear Medicine ·D. L. Costantini, Conrad Chan, Zhongli Cai, Katherine A. Vallis, Raymond M. Reilly	2007	148
2	Optimized digital counting colonies of clonogenic assays using ImageJ software and customized macros: Comparison with manual counting International Journal of Radiation Biology ·Zhongli Cai, Niladri Chattopadhyay, Wenchao Jessica Liu, Conrad Chan, Jean‐Philippe Pignol, Raymond M. Reilly	2011	91
3	Cellular Dosimetry of ¹¹¹In Using Monte Carlo N-Particle Computer Code: Comparison with Analytic Methods and Correlation with In Vitro Cytotoxicity Journal of Nuclear Medicine ·Zhongli Cai, Jean‐Philippe Pignol, Conrad Chan, Raymond M. Reilly	2010	54
4	A human transferrin-vascular endothelial growth factor (hnTf-VEGF) fusion protein containing an integrated binding site for (111)In for imaging tumor angiogenesis. PubMed ·Conrad Chan, Jasbir Sandhu, Abhijit Guha, Deborah A. Scollard, Judy Wang, Paul Chen, Karen Bai, Lydia Lee, Raymond M. Reilly	2005	42
5	Development and preclinical studies of ⁶⁴Cu-NOTA-pertuzumab F(ab′)₂ for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT mAbs ·Karen Lam, Conrad Chan, Raymond M. Reilly	2016	41
6	Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF Nuclear Medicine and Biology ·Meiduo Hu, Deborah A. Scollard, Conrad Chan, Paul Chen, Katherine A. Vallis, Raymond M. Reilly	2007	36
7	Dual-Receptor–Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using ¹⁷⁷Lu- or ¹¹¹In-Labeled Bispecific Radioimmunoconjugates Journal of Nuclear Medicine ·Eva J. Razumienko, J. Chen, Zhongli Cai, Conrad Chan, Raymond M. Reilly	2015	35
8	Synthesis of Polyglutamide-Based Metal-Chelating Polymers and Their Site-Specific Conjugation to Trastuzumab for Auger Electron Radioimmunotherapy Biomacromolecules ·Yijie Lu, Ghislaine Ngo Ndjock Mbong, Peng Liu, Conrad Chan, Zhongli Cai, Dirk Weinrich, Amanda J. Boyle, Raymond M. Reilly, Mitchell A. Winnik	2014	34
9	Site-specific conjugation of HIV-1 tat peptides to IgG: a potential route to construct radioimmunoconjugates for targeting intracellular and nuclear epitopes in cancer European Journal of Nuclear Medicine and Molecular Imaging ·Meiduo Hu, Paul Chen, Judy Wang, Conrad Chan, Deborah A. Scollard, Raymond M. Reilly	2005	34
10	A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT EJNMMI Research ·Conrad Chan, Deborah A. Scollard, Kristin McLarty, Serena Smith, Raymond M. Reilly	2011	33
11	Trastuzumab Labeled to High Specific Activity with 111In by Conjugation to G4 PAMAM Dendrimers Derivatized with Multiple DTPA Chelators Exhibits Increased Cytotoxic Potency on HER2-Positive Breast Cancer Cells Pharmaceutical Research ·Conrad Chan, Zhongli Cai, Raymond M. Reilly	2013	23
12	Trastuzumab Labeled to High Specific Activity with ¹¹¹In by Site-Specific Conjugation to a Metal-Chelating Polymer Exhibits Amplified Auger Electron-Mediated Cytotoxicity on HER2-Positive Breast Cancer Cells Molecular Pharmaceutics ·Ghislaine Ngo Ndjock Mbong, Yijie Lu, Conrad Chan, Zhongli Cai, Peng Liu, Amanda J. Boyle, Mitchell A. Winnik, Raymond M. Reilly	2015	23
13	Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with ⁸⁹Zr-Labeled Trastuzumab-DM1: A Comparison with ⁸⁹Zr-Labeled Trastuzumab Molecular Pharmaceutics ·Noor Al‐saden, Karen Lam, Conrad Chan, Raymond M. Reilly	2018	19
14	A kit to prepare 111In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer Nuclear Medicine and Biology ·Deborah A. Scollard, Conrad Chan, Claire Holloway, Raymond M. Reilly	2010	18
15	111In- or 99mTc-labeled recombinant VEGF bioconjugates: in vitro evaluation of their cytotoxicity on porcine aortic endothelial cells overexpressing Flt-1 receptors Nuclear Medicine and Biology ·Conrad Chan, Zhongli Cai, Ruifen Su, Raymond M. Reilly	2009	16
16	Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice Nuclear Medicine and Biology ·Kristin McLarty, Matthew Moran, Deborah A. Scollard, Conrad Chan, Nesrin Sabha, Joydeep Mukherjee, Abhijit Guha, JoAnne McLaurin, Mark Nitz, Sylvain Houle, Alan A. Wilson, Raymond M. Reilly, Neil Vasdev	2011	15
17	Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of 111In-BzDTPA-pertuzumab Nuclear Medicine and Biology ·Karen Lam, Conrad Chan, Susan J. Done, Mark N. Levine, Raymond M. Reilly	2014	15
18	MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with ^99mTc(I) Tricarbonyl Complex Molecular Pharmaceutics ·Anthony Ku, Conrad Chan, Sadaf Aghevlian, Zhongli Cai, David W. Cescon, Scott V. Bratman, Laurie Ailles, David W. Hedley, Raymond M. Reilly	2019	12
19	Advancing Novel Molecular Imaging Agents from Preclinical Studies to First-in-Humans Phase I Clinical Trials in Academia—A Roadmap for Overcoming Perceived Barriers Bioconjugate Chemistry ·Raymond M. Reilly, Karen Lam, Conrad Chan, Mark N. Levine	2015	11
20	The electron-dose distribution surrounding an 192Ir wire brachytherapy source investigated using EGS4 simulations and GafChromicTM film Applied Radiation and Isotopes ·Yun‐Chung Cheung, Kaiyuan Yu, E. C. M. Young, Conrad Chan, Michelle Ng, Francis Tang, Tony Wong	1997	10

About Conrad Chan

Conrad Chan is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Immunology and Allergy, Radiation and Biophysics, having authored 32 papers that have together received 772 indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (26 papers), HER2/EGFR in Cancer Research (17 papers), Monoclonal and Polyclonal Antibodies Research (17 papers), Medical Imaging Techniques and Applications (6 papers), Lung Cancer Treatments and Mutations (3 papers), Cancer Immunotherapy and Biomarkers (3 papers), Advanced Radiotherapy Techniques (2 papers) and Advanced X-ray and CT Imaging (2 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (504 citations), Structural Biology (15 citations), Oncology (261 citations), Radiation (64 citations) and Biophysics (30 citations). Conrad Chan has collaborated with scholars based in Canada, United Kingdom and Hong Kong. Frequent co-authors include Raymond M. Reilly, Zhongli Cai, Katherine A. Vallis, Deborah A. Scollard, Jean‐Philippe Pignol, Karen Lam, Paul Chen, Niladri Chattopadhyay, Judy Wang and Yijie Lu. Their work appears in journals such as Nuclear Medicine and Biology, Molecular Pharmaceutics, EJNMMI Radiopharmacy and Chemistry, Applied Radiation and Isotopes and Journal of Nuclear Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact